Updated Guidelines Recommend Rubraca for Some Prostate Cancer Patients

Updated Guidelines Recommend Rubraca for Some Prostate Cancer Patients
Only a couple of weeks after Rubraca (rucaparib) was approved for the treatment of prostate cancer, the National Comprehensive Cancer Network (NCCN) has updated its guidelines recommending this PARP inhibitor as an option for select prostate cancer patients in the U.S. According to Clovis Oncology, which makes Rubraca, the NCCN recommends Rubraca as a "treatment option for patients with mCRPC [metastatic castration-resistant prostate cancer] and a pathogenic BRCA1 or BRCA2 mutation (...) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy." Also, "if the patient is not fit for chemotherapy, rucaparib [Rubraca] can be considered even if taxane-based therapy has not been given," the guidelines state. The NCCN Clinical Practice Guidelines in Oncology are a comprehensive set of guidelines that provide detailed recommendations for the sequential management of cancer patients based on the best avail
Subscribe or to access all post and page content.